Eloralintide
aka LY3841136
Investigational long-acting amylin receptor agonist (Eli Lilly, code LY3841136) studied for appetite regulation and weight reduction. Early-stage clinical development.
Sequence
Mechanism of action
Eloralintide (LY3841136) is a long-acting, selective amylin receptor agonist. Like other amylin analogs it activates amylin receptors in the central nervous system, particularly the area postrema and nucleus tractus solitarius, to promote satiety, reduce food intake and slow gastric emptying. It is being investigated for weight management and metabolic research. Unlike cagrilintide, a dual amylin and calcitonin receptor agonist, it is reported to act more selectively at the amylin receptor.
What the evidence actually shows
Early clinical development (Phase 1/2). Preliminary data support amylin-receptor-mediated appetite suppression and weight reduction; long-term and comparative efficacy data are still emerging. Added manually, verify or re-run enrichment for full depth and citations.
Regulatory status
Dosing — what backs each figure
Eloralintide (LY3841136) is Eli Lilly's investigational selective amylin receptor agonist; published human dosing is once-weekly subcutaneous 1-9 mg (fixed or stepped 3/6/9 mg escalation) over 48 weeks in phase 2, with single ascending doses of 0.04-12 mg in phase 1. It is not approved anywhere and there is no cycled regimen - dosing in trials is continuous.
Once-weekly subcutaneous injections at fixed doses of 1 mg, 3 mg, 6 mg or 9 mg, or escalation regimens 6/9 mg and 3/6/9 mg, over 48 weeks vs placebo
adults 18-75 with BMI >=30, or >=27 with at least one weight-related comorbidity, without type 2 diabetes; n=263 across 46 US centres · subcutaneous
Once-weekly subcutaneous dosing without dose escalation for 12 weeks, in 5 multiple-ascending-dose cohorts
100 participants with obesity or overweight (mean BMI 32.6), 3 US centres · subcutaneous
Single ascending doses of 0.04 mg to 12 mg
healthy participants, phase 1 randomised placebo-controlled trial (NCT05295940) · subcutaneous
Eloralintide (LY3841136) discovery-to-proof-of-concept paper, 2025 ↗
In vivo characterisation of eloralintide's receptor selectivity and conditioned taste avoidance relative to cagrilintide; doses in full text
rat and monkey · parenteral (subcutaneous) · PMID 41109426
Animal doses do not convert to human doses by body weight alone. Route matters too — a compound dosed intraperitoneally in mice tells you little about subcutaneous use.
Handling and storage
Safety
References (3)
- Billings LK, Hsia S, Bays H, Tidemann-Miller B, O'Hagan J, Tham LS, Butler A, Kazda C, Mather KJ, Coskun T (2025) Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial ↗LancetPMID 41207310DOI
48-week phase 2 randomised placebo-controlled trial of a range of once-weekly eloralintide doses and dose-escalation schemes in adults with obesity or overweight plus at least one weight-related complication.
- Briere DA, Qu H, Lansu K, He MM, Moyers JS, Coskun T, et al. (Eli Lilly and Company) (2025) Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept ↗Mol MetabPMID 41109426DOI
Discovery paper plus a phase 1 randomised, placebo-controlled single-ascending-dose trial in healthy participants (NCT05295940) with doses of 0.04-12 mg administered; in vitro, eloralintide preferentially activated human AMY1R (12-fold over CTR, 11-fold over AMY3R).
- Bhattachar S, Tham LS, Tidemann-Miller B, Ibriga H, Qu H, Briere DA, Haupt A, Mather KJ, Pratt E (2026) Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept ↗Diabetes Obes MetabPMID 41559929DOI
12-week phase 1 randomised, placebo-controlled multiple-ascending-dose study in 100 participants with obesity or overweight at three US centres (30 March 2022 to 25 January 2024), evaluating once-weekly subcutaneous dosing without dose escalation.
Data provenance
Chemistry and citations on this page were checked against primary sources on 2026-08-14. Values that could not be verified were left blank rather than filled with a plausible guess.
Could not verify
sequence, storage, reconstitution